TD-HW338056

Vulinacimab(TD-HW338056) is a research-grade recombinant antibody targetingCD309. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Human

IgG1-kappa

Monoclonal

FLK-1, Kinase insert domain receptor, VEGFR2, Fetal liver kinase 1, CD309, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, FLK1, VEGFR-2, KDR

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P35968

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

HLX-06, HLX06, 2250342-36-8

Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab')2 fragment of a monoclonal antibody.• Flk-1/KDR mediates ethanol-stimulated endothelial cell Notch signaling and angiogenic activity., PMID:25322777• VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial., PMID:37393757• Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma., PMID:24880461• Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal., PMID:28410224

SDS-PAGE for Research Grade Vulinacimab

For research use only. Not suitable for clinical or therapeutic use.